Pure red-cell aplasia and epoetin therapy Academic Article uri icon

Overview

MeSH Major

  • Erythropoietin
  • Red-Cell Aplasia, Pure

abstract

  • After the peak incidence of Eprex-associated pure red-cell aplasia was reached in 2001, interventions designed in response to drug-monitoring programs worldwide resulted in a reduction of more than 80 percent in the incidence of pure red-cell aplasia due to Eprex.

publication date

  • September 30, 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa040528

PubMed ID

  • 15459301

Additional Document Info

start page

  • 1403

end page

  • 8

volume

  • 351

number

  • 14